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The IKK [IκB (inhibitory κB) kinase] complex is a key
regulatory component of NF-κB (nuclear factor κB) activation
and is responsible for mediating the degradation of IκB, thereby
allowing nuclear translocation of NF-κB and transcription of
target genes. NEMO (NF-κB essential modulator), the regulatory
subunit of the IKK complex, plays a pivotal role in this process
by integrating upstream signals, in particular the recognition
of polyubiquitin chains, and relaying these to the activation of
IKKα and IKKβ, the catalytic subunits of the IKK complex. The
oligomeric state of NEMO is controversial and the mechanism
by which it regulates activation of the IKK complex is poorly
understood. Using a combination of hydrodynamic techniques
we now show that apo-NEMO is a highly elongated, dimeric
protein that is in weak equilibrium with a tetrameric assembly.
Interaction with peptides derived from IKKβ disrupts formation
of the tetrameric NEMO complex, indicating that interaction with
IKKα and IKKβ and tetramerization are mutually exclusive.
Furthermore, we show that NEMO binds to linear di-ubiquitin
with a stoichiometry of one molecule of di-ubiquitin per NEMO
dimer. This stoichiometry is preserved in a construct comprising
thesecondcoiled-coilregionandtheleucinezipperandinonethat
essentially spans the full-length protein. However, our data show
that at high di-ubiquitin concentrations a second weaker binding
site becomes apparent, implying that two different NEMO–
di-ubiquitin complexes are formed during the IKK activation
process. We propose that the role of these two complexes is
to provide a threshold for activation, thereby ensuring sufﬁcient
speciﬁcity during NF-κB signalling.
Key words: analytical ultracentrifugation (AUC), IKK (inhibitory
κB kinase) complex, isothermal titration calorimetry (ITC),
multi-angle light scattering (MALS), protein–protein interaction,
ubiquitin.
INTRODUCTION
NF-κB(nuclearfactorκB)transcriptionfactorsarekeyregulators
of immune and inﬂammatory responses (reviewed in [1,2]). In
unstimulated cells they are foundin complex with IκB (inhibitory
κB)proteins,aninteractionthatpreventstheirtranslocationtothe
nucleus and retains NF-κBs in the cytosol. Stimulus-dependent
phosphorylationof IκBs inducestheir Lys
48-linked ubiquitination
andsubsequentdegradationbythe26Sproteasome,therebyliber-
ating NF-κB and allowing nuclear translocation. A key regulator
of this process is the multi-subunit IKK (IκB kinase) complex
(sometimes referred to as the signalosome), which is composed
of two kinases, IKKα and IKKβ, and a non-catalytic regulatory
subunit called IKKγ or NEMO (NF-κB essential modulator) [3–
5]. The apparent molecular mass of the resting IKK complex
has been shown to be in the 700–900 kDa range, suggesting
that it may contain multiple copies of its constituents [6–8].
Nonetheless, its precise composition is controversial, and it may
be that its size varies in a stimulus-dependent manner [9]. NEMO
is the regulatory hub of the IKK complex and integrates multiple
signals, including phosphorylation, ubiquitination and interaction
with ubiquitin chains [10]. In addition to being the target of
multiple post-translational modiﬁcations, NEMO also acts as an
assembly platform that facilitates the incorporation of a variety
of proteins into the IKK signalosome, such as the viral proteins
vFLIP {viral FLICE [FADD (Fas-associated death domain)-like
interleukin 1β-converting enzyme]-inhibitory protein} and Tax,
which can act as potent activators of NF-κB [11,12].
NEMOisa∼50 kDaproteinpredictedtoconsistoftwocoiled-
coil regions, CC1 and CC2, a LZ (leucine zipper) and a ZF (zinc
ﬁnger) (Figure 1). In spite of extensive studies aimed at deﬁning
the assembly of NEMO, its oligomeric state still remains a matter
of some controversy. The apo form of the full-length protein
has variously been described as monomeric, dimeric, trimeric or
tetrameric state [13–15]. A number of studies have suggested that
thesecondcoiled-coilregion,togetherwiththeLZ,constitutesthe
minimal oligomerization domain (from now on referred to as
CoZi) [15,16]. However, similar to the full-length protein, the
oligomeric state of this region is not clear and has, for example,
beendescribedasatrimerthatcanassociateto‘pseudo-hexamers’
upon appropriate stimulation [16]. In contrast, two recent crystal
structures of this region have shown it forms a parallel, dimeric
coiled-coil, in accordance with other studies that reported
a dimeric assembly [15,17–19]. The oligomeric state of the
N-terminal coiled-coil region is similarly unresolved, and a range
of oligomeric states have been reported [20–22].
A key step towards a better understanding of the regulatory
role of NEMO in NF-κB activation was the observation that
NEMO interacts speciﬁcally with polyubiquitin chains ([23],
but see [23a], [24]). These experiments initially utilized linear
(‘genetically linked’, i.e. Gly
76 to Met
1 linked) polyubiquitin
chains in a yeast two-hybrid screen. However, Lys
63-linked
ubiquitin chains attached to RIP1 (receptor interaction protein
kinase) are believed to be the physiological targets ([23], but see
[23a]). This interaction is suggested to recruit the IKK complex
to receptor complexes and thereby promote the subsequent
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Figure 1 Structure and purity of protein constructs used in the present study
(A) Schematic representation of the domain structure of NEMO and the constructs used in the present study. (B) Coomassie Blue-stained SDS/polyacrylamide gel showing the purity of the protein
preparations used. The faint bands on the NEMO355 and CoZi lanes at twice the molecular mass represent incompletely denatured dimers. Molecular masses are shown to the left in kDa.
activation of the kinase activity of IKKα and IKKβ.T h e
binding site for ubiquitin has been mapped to a region of
NEMO that has homology with ABIN (A20-binding inhibitor
of NF-κB) and optineurin and has been named the NUB or
UBAN motif ([23], but see [23a], [24,25]). This conserved
binding region is located within the CoZi domain. Although
a number of studies have shown that speciﬁc recognition of
K63-linked ubiquitin chains is important for NF-κB activation
([23], but see [23a], [24]), it has recently been reported that
linear di-ubiquitin binds with a 100-fold higher afﬁnity to the
CoZi domain than K63-linked di-ubiquitin [17,18,26]. This
observation is particularly interesting in the light of a recent
report that NEMO itself becomes modiﬁed with linear ubiquitin
chains that are attached by the ligase complex LUBAC [27].
In the present study we have applied a combination of
complementary hydrodynamic methods to deﬁne the oligomeric
state of NEMO and resolve the current controversy surrounding
its self-association. We show that apo-NEMO forms a tight dimer
thatisinarelativelyweakequilibriumwithatetramericassembly.
Importantly, binding of IKKβ-derived peptides prevented
formation of the tetramer, indicating that the IKK-binding region
in the N-terminal portion of NEMO is responsible for the
formationofhigher-molecular-massspeciesandthatIKKbinding
andtetramerizationaremutuallyexclusive.Furthermore,weshow
that the CoZi domain and a nearly full-length NEMO construct
bind di-ubiquitin with similar afﬁnities but slightly different
energetics. These results suggest that no major conformational
changestakeplaceuponinteractionwithubiquitinchains,butthat
minor rearrangements may be induced in the N-terminal coiled-
coil region. Surprisingly, only one di-ubiquitin chain binds to
the symmetrical NEMO dimer. However, a second binding site
becomes apparent at high ubiquitin concentrations, implying that
two different NEMO/polyubiquitin complexes are formed during
the activation process. This observation may have implications
for the in vivo function of NEMO and suggests that association
with protein assemblies that provide a high density of poly-
ubiquitin chains might induce clustering of NEMO, which in
turn will lead to activation of the IKK complex.
EXPERIMENTAL
Plasmids
The cDNA for full-length mouse and human NEMO and the
expression plasmid for di-ubiquitin were kindly provided by Dr
F.Randow(MRC-LMB,Cambridge,U.K.).NEMOresidues251–
355 (CoZi), NEMO (residues 1–355, C54S, K285N referred to
as NEMO355) and human NEMO residues 218–363 were cloned
into the pGEX-6P1 expression vector. The C54S mutation was
introduced to prevent disulﬁde bond formation, K285N has been
described in [19]. Bovine mono-ubiquitin was purchased from
Sigma.
Protein puriﬁcation
For CoZi puriﬁcation, Escherichia coli BL21(DE3) cells
containing the plasmid were grown in LB (Luria–Bertani) broth
at 37◦Ct oaD600 of ∼0.8. Protein expression was induced by
the addition of 0.5 mM IPTG (isopropyl β-D-thiogalactoside)
and cells were incubated for a further 3 h. Cell pellets were
resuspended in Buffer A {50 mM Tris/HCl, pH 8, 500 mM NaCl
and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine]}, lysed by
sonication and the crude lysate was applied to a pre-equilibrated
glutathione–Sepharose column (GE Healthcare) at 1 ml/min.
Bound protein was eluted with Buffer A containing 20 mM
reduced glutathione. The GST afﬁnity tag was removed by the
addition of 3C protease and incubation at 4◦C overnight.
The sample was concentrated in 10-kDa-molecular-mass-cut-off
Vivaspin concentrators (Sartorius) and applied to a Superdex 75
column (GE Healthcare) pre-equilibrated with Buffer B (50 mM
Tris/HCl, pH 8, 100 mM NaCl and 0.5 mM TCEP). Fractions
containing CoZi were pooled and loaded on to another GSH
column to remove contaminating GST and 3C protease. CoZi
was concentrated to 20 mg/ml.
For NEMO355 puriﬁcation, expression was carried out in
Rosetta2(DE3)pLysS cells at 18◦C for 16 h. Cell pellets were
resuspended in Buffer
GST (20 mM Tris/HCl, pH 8, 500 mM NaCl,
10% glycerol and 0.25 mM TCEP) and lysed by sonication.
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Crude lysate was applied to a column of glutathione–Sepharose
resin followed by extensive washing with Buffer
GST.T h eG S T
afﬁnity tag was removed on-column by overnight incubation
with 1.5 mg of 3C protease. GST-free NEMO355 was eluted in
Buffer
Q (20 mM Tris/HCl, pH 8, 50 mM NaCl, 10% glycerol
and 0.25 mM TCEP) and applied to a Source Q ion-exchange
column (GE Healthcare). The sample was eluted with a 1 M
NaCl 20 column volume gradient in Buffer
Q, and concentrated to
5 ml on a 50-kDa-molecular-mass-cut-off Vivaspin concentrator.
The sample was then applied to a Superdex 200 size-exclusion
column pre-equilibrated in Buffer
GST. The relevant fractions were
concentrated to 13.7 mg/ml.
For linear di-ubiquitin puriﬁcation, expression was carried out
in BL21(DE3) cells for 3 h at 37◦C. Puriﬁcation was carried
out as described previously for CoZi, except that the afﬁnity tag
was removed by incubation with TEV protease instead of 3C
protease. Pure protein was concentrated using-5-kDa-molecular-
mass-cut-off Vivaspin columns to 13.3 mg/ml.
Protein concentrations were determined by UV spectrometry
using calculated 280 nm molar absorption coefﬁcients. Con-
centrations were conﬁrmed by analysis of the differential RI
(refractive index) eluate peaks from the SEC (size-exclusion
chromatography)-MALS (multi-angle light scattering) experi-
ments described below. Speciﬁcally, integration of an RI peak
yields a total mass that, in conjunction with known loading
volume, allows determination of the loading concentration in-
dependent of UV absorbance. Concentration values from both
methods were in good agreement. Furthermore, expected formula
molecular masses were conﬁrmed for each protein using MS.
ITC (isothermal titration calorimetry)
All samples were extensively dialysed into fresh buffer [50 mM
Tris/HCl, pH 8, 0.5 mM TCEP and 100 mM NaCl (CoZi) or
150 mMNaCl(NEMO355)].Proteinconcentrationwasdetermined
by UV absorbance and conﬁrmed by the integration of RI
peaks from SEC-MALS (see below). ITC measurements were
carried out at 10◦C, 18◦C and 25◦C on a VP-ITC or ITC200
MicroCalorimeter (MicroCal Inc). In most cases, ITC titrations
were carried out with 29 consecutive 10 μl injections of ubiquitin
into the cell containing NEMO on the VP-ITC or alternatively
with 19 consecutive 2 μl injections on the ITC200 instrument (all
at various concentrations). ITC data were analysed with Origin7
software(MicroCal)suppliedbythemanufacturer.Theheatcapa-
city change was determined from the slope of a linear regression
ﬁt of  H plotted against the temperature of the titration.
MALS
Molecular mass and molecular-mass distributions were deter-
mined using on-line SEC-MALS. Samples were applied in
a volume of 100 μl to a Superdex 200 10/300 GL column
equilibrated in 20 mM Tris/HCl, 150 mM NaCl and 0.25 mM
TCEP, pH 8.0, at a ﬂow rate of 0.5 ml/min. The column was
mounted on a Jasco HPLC controlled by the Chrompass software
package. The scattered light intensity of the column eluate
was recorded at 16 angles using a DAWN-HELEOS laser
photometer (Wyatt Technology, Santa Barbara, CA, U.S.A.).
The protein concentration of the eluent was determined from the
RI(n) change (dn/dc=0.186) (where c is solute concentration)
using an OPTILAB-rEX differential refractometer equipped
with a Peltier temperature-regulated ﬂow cell, maintained at
25◦C (Wyatt Technology). The wavelength of the laser in the
DAWNHELEOS and the light source in the OPTILABrEX
was 658 nm. The weight-averaged molecular mass of material
contained in chromatographic peaks was determined using
the ASTRA software version 5.1 (Wyatt Technology Corp.,
Santa Barbara, CA). Brieﬂy, at 1 s intervals throughout the
elution of peaks, the scattered-light intensities, together with
the corresponding protein concentrations, were used to construct
Debye plots [KC/Rθ against sin
2(θ/2)]. The weight-averaged
molecular mass was then calculated at each point in the
chromatogram from the intercept of an individual plot. An overall
average molecular mass and polydispersity term for each species
was calculated by combining and averaging the results from the
individual measurements.
Sedimentation-velocity AUC (analytical ultracentrifugation)
Sedimentation-velocity experiments were performed in a
Beckman Optima Xli analytical ultracentrifuge, using conven-
tional charcoal-ﬁlled Epon double-sector quartz cells or
aluminium double-sector sapphire cells in an An-50 Ti rotor. The
rotor speed was 40000 rev./min or 50000 rev./min respectively,
and the temperature was maintained at 293 K. Prior to centri-
fugation, protein samples were dialysed exhaustively against
the buffer blank (10 mM Tris/HCl, pH 8.0, 150 mM NaCl and
0.25 mM TCEP). The protein concentration was varied from
0.37 mg/ml to 1.76 mg/ml. Interference images were collected
every 180 s during the sedimentation run. The data recorded from
moving boundaries were analysed by the program SEDFIT in
termsofbothdiscretespeciesandcontinuousdistributionfunction
of sedimentation coefﬁcient [c(s)].
RESULTS
NEMO355 exists in a dimer/tetramer equilibrium
In order to resolve the discrepancies concerning the exact
multimeric state of NEMO, the solution molecular mass of
a construct containing all of the predicted coiled-coil regions
was examined by SEC coupled to MALS (SEC-MALS). This
construct is missing only the C-terminal ZF, which has been
shown to be monomeric [28] and will be referred to from now
on as NEMO355 (Figure 1). SEC-MALS allows the determination
of an absolute molecular mass during analytical gel ﬁltration,
independent of the shape of the molecule under investigation,
and hence is well suited to determine the oligomeric state
of proteins. An initial MALS experiment reports a weight-
averaged molecular mass (MW) of 85.7 kDa for an average
peak concentration of 1.4 μM, a value in close agreement with
the formula molecular mass of dimeric NEMO355 (83.8 kDa).
However, at increased concentrations, elevated MW values are
apparent, a phenomenon that was unaffected when the NaCl
concentration was increased to 500 mM (results not shown). We
therefore analysed the concentration-dependent MW of NEMO355
further with a sequence of SEC-MALS analyses ranging from 1.4
to 16.9 μM (average peak concentration), as shown in Figure 2.
These experiments reported corresponding MW values of 85.7–
113.8 kDa and clearly demonstrate that NEMO355 is subject to
concentration-dependent self-association based upon a minimum
assembling unit equivalent to a dimer. The assembly of dimers
into tetramers is the simplest model explaining these data.
In order to characterize further the size of the multimers
involved in self-association, we investigated NEMO355 using
sedimentation velocity AUC at three concentrations: 8.8 μM,
17.6 μM,and42 μM(monomerconcentration).C(S)distribution
analyses of the data clearly showed the presence of two
major species centred at s20,w values of approx. 3 and 4 S
(Figure2).ConsistentwiththeMALSdataabove,therelativepeak
proportions varied in a concentration-dependent manner. At low
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Figure 2 NEMO355 is dimeric and exists in a concentration-dependent equilibrium with a higher order species
(A) SEC-MALS measurements of NEMO355 (dimeric formula Mr 83.8kDa) loaded at concentrations ranging from 0.5 to 8.0mg/ml. Refractive index-derived weight concentrations (mg/ml) of the
peaks are shown to the right. For clarity, derived Mw (kDa) of the peaks are shown separately to the left along with a legend detailing the peak Mw for each experiment. (B) NEMO355 exists in a
dimer/tetramer equilibrium. Sedimentation velocity experiments of NEMO355 at three concentrations (8.8, 17.6 and 42μM) shown as best-ﬁt c(s) functions.
concentration, the predominant peak was centered on the lower
s20,w value, whereas the reverse was true at higher concentration.
At intermediate concentration (17.6 μM), the peaks were nearly
indistinguishable. As the peaks were fully separated in the c(s)
function for the low-concentration experiment, we were able to
analyse these data as discrete species. The data ﬁtted well to a
two-component discrete species model with s20,w values of 3.00
and 4.23 and Dt,20,w (translational diffusion coefﬁcient) values
of 3.48 and 2.30 respectively (Figure 2 and Table 1). The
respective MW values calculated from these values are 77.6
and 164.9 kDa. These values are in good agreement with the
molecular mass expected from NEMO355 dimers (83.8 kDa)
and tetramers (167.6 kDa). Using the relative peak proportions
from the c(s) function for the low concentration experiment
(8.8 μM), an apparent dissociation constant (Kd) of 25.6 μM
(dimer–tetramer equilibrium) was obtained. Notably, a ﬁt of the
SEC-MALS concentration-dependent data to a two-state self-
association model resulted in an apparent Kd of 27.5 μM (results
not shown).
In order to help identify the region responsible for NEMO
tetramerization, isolated NEMO CoZi domain was also subjected
to sedimentation-velocity analysis at 46, 93 and 139 μM
monomer concentration (results not shown). The data from this
experiment ﬁtted well to a discrete species model showing
a single signiﬁcant component and Mw with a range of
25.0–27.8 kDa, consistent with the formula molecular mass
ofdimericCoZidomain(25.9 kDa)(seeTable3).Theseresultsdo
not indicate the presence of the tetramers evident in the NEMO355
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Table 1 Hydrodynamic parameters of the 8.8 μMN E M O 355 sedimentation
velocity experiment (discrete species model)
Mr, formula molecular mass; Vbar, partial speciﬁc volume; Mw, reported by experiment; s20,w,
sedimentation coefﬁcient; Dt,20,w, translational diffusion coefﬁcient; f/f0, frictional coefﬁcient
ratio; Kd, dissociation constant, calculated from known loading concentration and relative peak
proportionsforadimer–tetramerequilibrium;RMSD,averagerootmeansquaredeviationofthe
ﬁt. Parameters with only one value are independent of the particular species involved.
Parameters Dimer Tetramer
Mr (kDa) 83.8 167.6
Vbar 0.728 0.728
Mw (kDa) 77.6 164.9
s20,w 3.00 4.23
Dt,20,w 3.5 2.3
f/f0 2.3 2.6
Relative proportions 0.87 0.13
Kd (μM) 25.6 25.6
RMSD 0.057 0.057
construct, suggesting that the N-terminal region of NEMO is
responsible for higher-order self-association.
NEMO adopts a highly elongated conformation
Importantly, the discrete species analysis of the AUC data also
allowed us to calculate the frictional ratio (f/f 0) for CoZi and the
NEMO355 dimer and tetramer. The frictional ratio is a measure
of the degree of asymmetry in a molecule with respect to an
anhydrous sphere of the same mass. For CoZi, an f/f 0 of 1.7
was measured, which deviates considerably from the value (1.0)
characteristic of a spherical protein molecule and points towards
a highly elongated structure. Remarkably, the frictional ratios for
NEMO355 dimers and tetramers were signiﬁcantly higher, 2.3 and
2.6 respectively, demonstrating that both are unusually elongated
and asymmetric molecules in solution (Table 1).
IKK binding abolishes NEMO355 tetramerization
The most highly recognized function of NEMO within the NF-
κB signalling pathway is in the recruitment and regulation of
IKKsresponsibleforthephosphorylationandinactivationofIκB.
In order to further investigate the nature of the NEMO/IKK
interaction, we analysed a complex of NEMO355 and a 41-mer
peptide comprising the IKKβ NEMO-binding domain (IKKNBD;
4.7 kDa) by SEC-MALS analysis. The resulting Mw of the
complex (92 kDa) was in close agreement with the formula
molecular mass expected of dimeric NEMO355 bound to two
IKKNBD peptides (93.3 kDa) (Figure 3). This result agrees with a
recently published heterotetrameric crystal structure comprising
a short, dimeric NEMO N-terminal fragment bound to two
IKK peptides [29]. Interestingly, the Mw r e p o r t e db yS E C -
MALS remained constant over a wide NEMO355 concentration
range, demonstrating that the interaction is tight in accordance
with previous studies [20,29]. Moreover, it shows that binding
of IKKNBD completely abrogates the concentration-dependent
tetramerization of NEMO355. These results indicate that the IKK
binding and tetramerisation regions are overlapping. Importantly,
these data demonstrate that the oligomeric state of NEMO is
modulated by binding of speciﬁc ligands.
The CoZi/di-ubiquitin interaction
Most ubiquitin-binding domains characterized so far interact
with mono-ubiquitin, often with relatively low afﬁnities [30,31].
Figure 3 IKKβ C-terminal peptide tightly binds NEMO355 and abrogates
tetramerization
SEC-MALSmeasurementsofhighconcentrationNEMO355 (dimericformulaMr 83.8kDa)bound
toexcess41-merC-terminalIKKβ peptide(4.7 kDa).RI-derivedweightconcentrations(mg/ml,
leftaxis)ofthepeaksareshownfortheentierrun.Incorrespondinglinetypes,derivedapparent
molecularmass(kDa,rightaxis)areshownforthecentreofeachpeak.Shownforcomparisonis
a measurement of a comparable concentration of NEMO355 alone demonstrating an increase in
Mw causedbytetramerization.Apparentmolecularmassforthebindingexperiments(∼92kDa)
agreewiththeformulamolecularmassofdimericNEMO355boundtotwoIKKpeptides(93.3kDa).
NEMO also binds very weakly to mono-ubiquitin [19] and
surprisingly, only weakly to K63-linked di-ubiquitin, whereas the
interaction with linear di-ubiquitin is around 100-fold stronger
[17,18,26]. In order to understand better the thermodynamics
of the interaction with linear ubiquitin chains, we used ITC to
follow complex formation. No binding was detected between the
CoZi domain and mono-ubiquitin at three different temperatures
atconcentrationsof50 μMCoZiinthecelland500 μMubiquitin
in the syringe, indicating that any interaction must be very
weak (results not shown). Titration of CoZi with increasing
concentrations of di-ubiquitin at 18◦C resulted in heats of
interaction that weretoo small forquantitative analysis. However,
titrations at 25◦C and 10◦C produced sufﬁcient signal to be able
to ﬁt the binding isotherm, resulting in dissociation constants
of 1.4 and 2.6 μM respectively (see Table 2 and Figure 4A).
Surprisingly,thestoichiometryofcomplexformationwas∼0.5in
terms of polypeptide chains, demonstrating that one CoZi dimer
interacts with one molecule of di-ubiquitin. Given the pseudo-
symmetrical structure of dimeric CoZi [17,18], one might expect
that equivalent binding sites on each NEMO chain exist, and
hence that two molecules of di-ubiquitin would bind, one either
side(CoZidimer/2×di-ubiquitin).Incontrast,thesebindingstudies
suggest that the di-ubiquitin molecule interacts with NEMO in an
asymmetric fashion. To test if this binding mode is preserved
in the context of full-length NEMO, we titrated NEMO355
with di-ubiquitin. As observed with the isolated CoZi domain,
the enthalpy of complex formation was strongly temperature-
dependentandendothermicatlowertemperatures,butexothermic
at room temperature (25◦C) and above. Notably, the binding
stoichiometry and strength of complex formation are similar
to that found for the CoZi domain with Kd values of 0.95 μM
and 3.45 μMa t2 5 ◦C and 10◦C respectively (Table 2 and
Figure4B).However,thereissomedifferenceintheheatcapacity
change of complex formation, which is −587 cal·mol
− 1 ·K
− 1
(1 cal≈4.184 J) for CoZi and −360 cal·mol
− 1 ·K
− 1 for the
NEMO355 di-ubiquitin interaction (Figure 4C).
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Figure 4 NEMO complexes with di-ubiquitin
ITC titrations of (A) 49.5μM NEMO355 titrated with 453μM di-ubiquitin and (B) 112μM CoZi titrated with 693μM di-ubiquitin, both at 10◦C. (C) Enthalpies of complex formation are plotted as
a function of temperature. The change in heat capacity is the slope of a linear regression ﬁt.
Table 2 Thermodynamic parameters for the NEMO–di-ubiquitin interaction
All titrations were carried out three or fourtimes and the estimated error is the S.D. between
measurements.
Component in cell T N Kd (μM)  H (kcal/mol)
Mouse CoZi 10◦C0 . 5 3 + −0.06 2.6+ −0.4 4.8+ −0.6
25◦C0 . 6 2 + −0.07 1.4+ −1.0 −4.0+ −0.6
Mouse NEMO355 10◦C0 . 4 4 + −0.05 3.45+ −0.4 4.1+ −0.7
25◦C0 . 5 2 + −0.04 0.95+ −0.2 −1.3+ −0.5
Analysis of NEMO–ubiquitin interaction by AUC
To investigate further the composition of the CoZi–di-ubiquitin
complex and conﬁrm the stoichiometry suggested by our ITC
experiments, we characterized the CoZi–di-ubiquitin interaction
by sedimentation-velocity AUC, which allows direct observation
of the complex(es) under investigation. Multiple experiments
were performed in which molar ratios of CoZi dimer and
di-ubiquitin were varied (1:1, 1:2, 1:4 and 1:8; CoZidimer/di-
ubiquitin). Molar concentrations and the resulting hydrodynamic
data from these experiments are detailed in Table 3. In each
of the three experiments where di-ubiquitin was present in
stoichiometric excess, two discrete species were observed. The
smallest component in each experiment clearly represents free di-
ubiquitin, as the s20,w Dt,20,w and MW values closely correspond
to the values obtained from analysis of di-ubiquitin alone
(Table 3). In the 1:1 experiment, the largest and most abundant
component has a mass of 45.3 kDa, close to the predicted
molecular mass of a complex consisting of dimeric CoZi bound
to one di-ubiquitin chain (CoZidimer–di-ubiquitin=43.5 kDa).
As expected, increasing the excess of di-ubiquitin resulted
in increasing proportions of free di-ubiquitin. Unexpectedly,
Figure 5 CoZi and di-ubiquitin interact to form CoZidimer/di-ubiquitin and at
higher ubiquitin ratios CoZidimer/(di-ubiquitin)2
Best ﬁt C(S) functions for sedimentation velocity analysis of CoZi/di-ubiquitin (Ub2)
interaction(s).
however, the apparent molecular mass of the complex component
also increased with increasing excess of di-ubiquitin (Figure 5
and Table 3). At the highest ratio (1:8 CoZidimer/di-ubiquitin),
the apparent mass increased to 53.3 kDa. This trend suggests
formation of a complex containing a second di-ubiquitin bound
to dimeric CoZi. We used the weight-averaged molecular mass
(53.3 kDa) for the 1:8 experiment to determine the proportions
of CoZidimer/di-ubiquitin and CoZidimer/(di-ubiquitin)2, from which
wecanestimatea100-foldweakerbindingconstantforthesecond
di-ubiquitin binding site.
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Table 3 Hydrodynamic parameters of the CoZi/di-ubiquitin interaction(s)
Theﬁrstthreecolumnsdenotethecomposition,reducedratio,andmolarratiosrespectivelyatwhichthesedimentation-velocityexperimentswerecarriedout.Allparametersarederivedfromdiscrete
species modelling. Formula molecular mass: CoZidimer, 25.9kDa; di-ubiquitin, 17.5kDa; CoZidimer–di-ubiquitin, 43.5kDa; CoZidimer–(di-ubiquitin)2, 61.0kDa. Partial speciﬁc volumes (Vbar): CoZi,
0.737;di-ubiquitin,0.746;andaveragedVbar wasusedforCoZi–di-ubiquitincomplexes.Mw,reportedbyexperiment;s20,w,sedimentationcoefﬁcient;Dt,20,w,translationaldiffusioncoefﬁcient;f/f0,
frictional ratio; RMSD, averagerootmeansquaredeviation oftheﬁt. Dataareorganizedinto sectionspertainingeither to free(unbound)or complex speciesandthenatureofthefree speciesisnoted
as CoZidimer, di-ubiquitin or Mixture (a weight-averaged mixture of unbound species).
Concn. Free Complex
Ratio (μM) Free species s20,w Dt,20,w f/f0 Mw s20,w Dt,20,w f/f0 Mw RMSD
COZIdimer – 23 COZIdimer 1.76 6.5 1.7 25.0 – – – – 0.0042
Di-ubiquitin – 103 Di-ubiquitin 1.69 9.0 1.4 18.0 – – – – 0.0063
COZIdimer/di-ubiquitin 1:1 25:25 Mixture 2.08 9.3 1.6 20.9 2.55 5.3 1.7 45.3 0.0077
COZIdimer/di-ubiquitin 1:2 45:90 Di-ubiquitin 1.76 9.1 1.3 17.9 2.67 5.7 1.6 43.7 0.0180
COZIdimer/di-ubiquitin 1:4 25:100 Di-ubiquitin 1.71 9.0 1.3 17.9 2.76 5.7 1.5 45.9 0.0180
COZIdimer/di-ubiquitin 1:8 25:200 Di-ubiquitin 1.71 9.7 1.3 16.6 2.89 5.1 1.5 53.3 0.0160
DISCUSSION
NEMO is the key regulatory component of the IKK complex
that senses upstream stimulatory events and relays them to the
activation of IKKα and IKKβ. A large proportion of the protein
is predicted to form coiled coils, including the regions that
are involved in ubiquitin recognition and interaction with the
catalytic IKK subunits. The molecular mechanism by which
NEMO induces activation of IKKα and IKKβ remains largely
unknown, although various models have been suggested. One
model assumes the CoZi domain undergoes stimulus-dependent
conformational changes that in turn might induce activation of
the kinases [19]. Alternatively, NEMO might act as a carrier
or platform that is responsible for bringing IKKα and IKKβ in
close proximity to activators such as TAK1 [TGFβ (transforming
growth factor β)-activated kinase-1] to promote phosphorylation
and activation ([23], but see [23a], [24]). On the other hand, the
interactionwithubiquitinchainsmayinduceclusteringofNEMO,
which could lead to IKK activation, possibly by inducing trans-
phosphorylation.
In the present study we have characterized the oligomeric state
of NEMO and its interaction with di-ubiquitin in order to provide
a molecular basis for a better understanding of its role in NF-κB
activation.
The oligomeric state of NEMO
The oligomeric state of NEMO has been controversial, and
a number of different models have been suggested for the
quaternary structure of the full-length protein as well as various
fragments. Using a combination of MALS and AUC, we show
that NEMO forms a very tight dimer that exists in a relatively
weak equilibrium (∼27 μM) with tetramers. Importantly, our ex-
tensive analysis shows that the protein preparations used in our
studyarehomogeneousandmonodisperse,andthatnoaggregates
are present that may interfere with the measurements. Our results
partiallyagreewithapreviousstudythatdescribedhumanNEMO
to predominantly form tetramers [15], but contradict a number of
othersthatdescribedNEMOasmonomersandtrimers[13,14,16].
The most likely explanation for this discrepancy is the presence
of detergent in the work by Agou and co-workers, which was,
apparently, required to prevent the formation of aggregates,
suggesting that the protein used in those studies may not have
been in its native conformation [13,14,16]. This interpretation
is supported by the presence of chaperone protein DnaK in the
proteinpreparationsusedforsomeofthestudies.Furthermore,we
believethatthevariousandhighlycontradictingoligomericstates
determined for different N-terminal constructs of NEMO [20,21]
are due to an inherent instability and heterogeneity of shorter
NEMO fragments, which may have compromised previous work.
This interpretation is supported by Rushe et al. [29] who reported
a similar lack of homogeneity for shorter N-terminal fragments
of NEMO.
In contrast with NEMO355, the CoZi domain has no tendency to
tetramerizeoverarangeofconcentrations.Furthermore,complex
formation with an IKKβ-derived peptide completely abolished
the ability of dimeric NEMO355 to form higher-order oligomers,
showing that the region surrounding the IKK-binding site is
responsible for tetramerization. These results from the present
study are in contrast with those of previous cross-linking studies,
which suggested that NEMO binds the IKKs in its tetrameric
form and that tetramerization is required for kinase activity [15].
It now seems likely that cross-linking studies have overestimated
the oligomeric state of NEMO due to non-speciﬁc association.
Nevertheless, the model that oligomerization of NEMO might be
part of the IKK activation mechanism is intriguing and is fully
compatible with the notion that binding to polyubiquitin chains
induces clustering of NEMO as described below. Importantly, the
observation that interaction with IKK abolishes tetramerization
clearly illustrates that the oligomeric state of NEMO in its ligand
complexes might differ from that of the apoprotein.
Similarly to full-length NEMO, the state of the minimal
oligomerizationdomain,CoZi,hasbeencontroversial.Tworecent
crystal structures of the apo form of this domain show it to form a
parallel coiled-coil domain that is approx. 120 Å (1 Å=0.1 nm)
in length [17,18]. This is in accordance with the results reported
here, yet contradicts a number of other studies that reported tri-
meric and hexameric assemblies [13,16]. A CoZi construct
comprising amino acids 250–339 has been reported to exist in
a monomer–dimer equilibrium with a Kd of 30 μM [19]. The
fragment used in the present study is slightly extended at
the C-terminus and includes amino acids 340–355, which are
not predicted to be part of the LZ. Interestingly, the inclusion
of this region signiﬁcantly strengthens dimerization, suggesting
that this C-terminal extension, which is absent in the crystallised
fragments, is part of the coiled-coil domain.
AUC studies of NEMO355 show that it adopts an extremely
elongated conformation, as illustrated by the frictional ratios
for NEMO355 dimers and tetramers (2.3 and 2.6 respectively).
These values are signiﬁcantly higher than would be expected
for a globular protein and are in fact similar to the value
measured for ﬁbrinogen (2.3), a rod-like protein that has been
s h o w nb ye l e c t r o nm i c r o s c o p yt oh a v ea na v e r a g ea x i a lr a t i o
(lengthdividedbydiameter)of7.5[32–34].Therecentlyreported
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structuresofNEMO44−111 boundtoIKK-derivedpeptides[29]and
NEMO150−272 bound to vFLIP [35] show the respective ligand-
bound fragments of NEMO form an elongated dimeric coiled-
coil. In combination with our AUC studies, these observations
indicate that binding of target proteins will not induce gross
conformational changes, but can alter oligomerization. Instead,
apo-NEMO forms a highly elongated coiled-coil that is poised to
accommodatethebindingofdifferentproteins,apparentlywithout
major structural rearrangements. Nevertheless, it is tempting to
speculate that binding to ligands may induce slight local changes
that are propagated along the coiled-coil, ultimately inducing
activation of IKKα and IKKβ.
The NEMO–polyubiquitin interaction
The interaction of NEMO with polyubiquitin chains is important
for the activation of the IKK complex in response to TNFα
stimulation ([23], but see [23a], [24]). Binding occurs via the
UBAN motif within the CoZi domain. The interaction of mono-
ubiquitin with CoZi is extremely weak, and we could not
detect any binding under the conditions of our ITC experiments,
although high sensitivity LUMIER (LUminescence-based
MammalianIntERactome)assaysshowedweakbindingcanoccur
[19]. In contrast, linear di-ubiquitin binds with an afﬁnity in the
low-micromolar range, clearly indicating that the interaction with
each individual ubiquitin is additive. Unexpectedly, binding of
NEMO to K63-linked di-ubiquitin is signiﬁcantly weaker than
to linear chains [17,18,26], suggesting that linear polyubiquitin
chains may be the true physiological targets [18].
The stoichiometry of the CoZi–di-ubiquitin interaction deter-
mined in our ITC experiments indicated that one NEMO dimer
interacts with one molecule of di-ubiquitin. This stoichiometry
is in accordance with an independent study by Lo et al. [17]
that also detected a 2:1 complex in solution. On the basis
of NMR chemical shift perturbations and mutagenesis studies,
these authors suggested a model for the complex in which di-
ubiquitin clasps around dimeric NEMO roughly perpendicular
to the long axis of the NEMO coiled-coil domain. However,
this stoichiometry and the derived model strongly contradict
the recently published CoZi/di-ubiquitin structure, which instead
shows two molecules of di-ubiquitin to bind to a NEMO dimer
in an orientation that is parallel with the coiled-coil axis [18].
Moreover, the authors of this study present NF-κB activation
assays with NEMO mutants defective in ubiquitin binding, which
support the notion that binding of two di-ubiquitin molecules
to NEMO is physiologically important. A simple explanation
for the apparent discrepancy between these studies could be the
partial dissociation of CoZi in the solution studies. However, this
explanation seems highly unlikely, as our AUC sedimentation
analysis of CoZi at concentrations used in the ITC experiments
shows that CoZi exists entirely in its dimeric form.
Interestingly, in solution NEMO355 shows similar binding
properties towards di-ubiquitin in terms of stoichiometry and
apparentafﬁnityastheCoZidomain,whereasthethermodynamic
characteristics of complex formation show small but distinctive
differences. This observation implies that binding of ubiquitin
does not induce any large conformational changes in the region
N-terminal to the CoZi domain, since this would probably be
reﬂectedintheafﬁnityoftheinteraction.Nevertheless,itindicates
that some communication exists between the CoZi domain and
the N-terminal part of NEMO.
To gain further insight into the CoZi–di-ubiquitin interaction
andunderstandtheapparentlyconﬂictingbindingstoichiometries,
we analysed complexes at different NEMO/di-ubiquitin ratios
by AUC. Sedimentation velocity experiments, at equimolar
concentrations of CoZi dimers and di-ubiquitin, showed a
complex of the molecular mass expected from the stoichiometry
observed in our ITC studies. Intriguingly, however, increases in
the relative ratio of di-ubiquitin over CoZi led to an increase
in the apparent molecular mass of the complex, suggesting that
at higher concentrations of di-ubiquitin a second binding site
in NEMO becomes occupied. Afﬁnity for this second site is
signiﬁcantly weaker, and thus it is possible that binding of
the ﬁrst molecule of di-ubiquitin may occlude binding of a
second. However, high ubiquitin concentrations might induce
slight structural rearrangements in NEMO, which in turn allow
the second binding site to become accessible. Alternatively, apo-
NEMOmightexistinanequilibriumbetweentwostates,ofwhich
only one may be capable of binding two di-ubiquitin chains. This
state might be unfavourable and hence would only be occupied at
highubiquitinconcentrations.However,crystallizationconditions
might have selected for this state over the other.
It is tempting to speculate that, in vivo, a multi-protein complex
containing ubiquitinated proteins such as RIP1 may provide the
high ubiquitin density required for occupation of the second site.
Population of the second site might be the trigger to initiate
IKK activation, possibly through clustering of NEMO. In fact,
this two-site binding event might constitute a ‘threshold for
activation’ to prevent non-speciﬁc activation of NF-κB, which
can have detrimental consequences for the host. Further studies
are now required to better characterize the in vivo role of these
two binding sites and understand the molecular events leading to
their formation.
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